Children with acute myeloid leukemia (AML) who come from neighborhoods with lower income have poorer outcomes and may have access to care issues, said Lena Winestone, MD, assistant professor of pediatrics at the University of California, San Francisco.
Children with acute myeloid leukemia (AML) who come from neighborhoods with lower income have poorer outcomes and may have access to care issues, said Lena Winestone, MD, assistant professor of pediatrics at the University of California, San Francisco.
Transcript
What have you found regarding how neighborhoods, specifically if they are those with low income and low education, impact survival in children with cancer?
So, we found that children with acute myeloid leukemia, a type of leukemia that affects children, have an increased risk of mortality if they come from a low-income or high-poverty neighborhood. In particular we looked at that and broke it down in several different ways. We looked at the risk of relapse and found that there was an increased risk of relapse among those patients. And in addition, we found that they had a higher risk of toxicity that led to mortality among that patient population.
Finally, we looked at early mortality as a marker, potentially, of access to care, and found that low-income patients also have a substantial increased risk of early mortality or death during the first course of chemotherapy, suggesting that a component of what’s going on may be related to access.
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Downward Morbidity, Mortality Trends Discovered Among Patients With Ovarian Cancer, Liver Metastases
April 24th 2024This study indicates a declining trend in morbidity and mortality rates among patients with ovarian cancer and liver metastases, highlighting the efficacy of surgery and chemotherapy in improving survival outcomes.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More